How does Agilent make money?

AGILENT TECHNOLOGIES, INC. – Business Breakdown

The Essentials

Agilent Technologies, Inc. is an application-focused provider of solutions across life sciences, diagnostics, and applied markets, with operations organized into three reporting segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The company generated $6.948 billion of net revenue in FY2025, up 7% year over year, and employed approximately 18,100 people as of October 31, 2025.

The business is structurally diversified across end markets and geographies, with no single customer representing more than 10% of revenue. Revenue is broadly balanced between the United States, China, and the rest of the world, underscoring a globally distributed commercial footprint. From an industrial standpoint, Agilent occupies an important position in analytical instrumentation, diagnostics, and laboratory workflow support, with a meaningful mix of product sales and recurring service/consumables revenue.

Business Model & Revenue Drivers

Agilent’s economic model is built around a combination of instrumentation, recurring services, consumables, and specialized application solutions. The revenue base is split across three segments:

• Life Sciences and Diagnostics Markets — $2.726 billion, 39% of FY2025 revenue

  • Grew 11% year over year.
  • Key drivers included CDMO activity, liquid chromatography (LC), LC mass spectrometry (MS), companion diagnostics, and pathology.
  • Growth was partially offset by a decline in academic/government demand.
  • End markets include pharma/biopharma, diagnostics/clinical, and academic/government.

• Agilent CrossLab — $2.908 billion, 42% of FY2025 revenue

  • Grew 6% year over year.
  • This is the company’s largest segment and appears central to recurring revenue quality.
  • Services include repairs, parts, maintenance, installations, training, compliance, SaaS, asset management, and consulting.
  • Also includes chemistries/supplies, lab automation, and software/informatics.
  • Growth was broad-based across pharma, chemical/advanced materials, and food.

• Applied Markets — $1.314 billion, 19% of FY2025 revenue

  • Grew 1% year over year.
  • Core technologies include gas chromatography (GC), GC-MS, remarketed instruments, spectroscopy, and vacuum.
  • Serves chemicals/advanced materials, food/environmental, and forensics.

Geographically, FY2025 revenue was distributed as follows:

• United States — $2.342 billion, 34%
• China (including Hong Kong) — $1.224 billion, 18%
• Rest of World — $3.382 billion, 48%

This mix suggests a business that is both globally diversified and exposed to regional capital spending cycles, particularly in research, diagnostics, and industrial applications.

Strategic Edge & Market Positioning

Agilent’s competitive position appears to be driven more by execution quality and installed-base monetization than by a clearly identifiable structural moat.

Economic Moat

• The filings do not support a strong conclusion that Agilent possesses a durable structural moat.
• While the company benefits from recurring service and consumables demand, the source explicitly indicates that switching costs are present but not proprietary, and that competitors offer similar multi-vendor support.
• The company operates in markets described as competitive and evolving, with no evidence in the filings of decisive patent barriers, network effects, or cost leadership.
• Instrumentation remains exposed to commoditization pressure, with competition based on performance, reliability, and price.

Execution Advantage

• Agilent appears to have a meaningful execution advantage in servicing a broad installed base through CrossLab, which supports recurring revenue and customer retention.
• Its global infrastructure, direct sales channels, and distributor relationships provide commercial reach, but these are operational strengths rather than structural defenses.
• The company’s ability to grow despite macro headwinds, tariffs, and capex sensitivity suggests disciplined commercial execution and portfolio management.
• Margin performance remains sensitive to external cost pressures; FY2025 gross margin was negatively affected by tariffs and shipping costs, reinforcing the absence of a hard cost advantage.

In short, Agilent’s positioning is best understood as a well-executed, diversified laboratory and diagnostics platform, not as a business protected by a clearly entrenched economic moat.

Outlook & Innovation Pipeline

The filings do not provide a formal three-year strategic plan, but they do indicate several priority vectors that likely define the company’s near-term roadmap:

• Expansion in CDMO and nucleic acid solutions

  • The company is investing in BIOVECTRA-related capabilities, including APIs for oligo therapeutics, antibody drug conjugates, and microbial fermentation.
  • Expansion in Frederick, Colorado is highlighted, with approximately $450 million of capex in FY2025 and potential partial reimbursement.

• Platform innovation in core analytical technologies

  • Continued development of LC/LC-MS and GC/GC-MS platforms remains central.
  • These systems are described as modular and upgradable, supporting research and clinical workflows.

• Cell analysis and genomics

  • Key platforms include Seahorse, xCELLigence, Novocyte, and BioTek in cell analysis.
  • In genomics, the company is focused on NGS reagents/arrays and SureSelect/SureDesign for mutation detection.

• Pathology and companion diagnostics

  • Automated IHC/ISH/H&E staining and pharma collaborations indicate continued emphasis on diagnostic workflow solutions.

• Commercial and capital discipline

  • The company is pursuing segment realignment to emphasize higher-margin services and consumables.
  • It is also maintaining capital allocation discipline through share repurchases, dividends, and targeted capex, while using restructuring to offset macro pressure.

R&D spending was $455 million in FY2025, down 5% year over year, which suggests a measured innovation posture rather than aggressive expansion. Overall, the pipeline appears oriented toward incremental platform enhancement, workflow integration, and targeted therapeutic/diagnostic adjacencies rather than a single transformative technology bet.